Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Viking Therapeutics Inc
VKTX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$26.89
0.18
0.69%
Dern. MÀJ: Oct 21, 10:54 AM
$26.80
0.09
0.34%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Viking Therapeutics Financials
Viking Therapeutics (VKTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today
Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.
Piero Cingari
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.
Evette Mitkov
PRO
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of $(0.58) per share from
Benzinga Newsdesk
PRO
Viking Therapeutics Q1 EPS $(1.37) Misses $(1.02) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.02) by 34.31 percent. This is a 234.15 percent decrease over losses of $(0.41) per share
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
Viking Therapeutics Stock Soars: What's Driving The Momentum?
Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.
Evette Mitkov
